| Budget Amount *help |
¥2,100,000 (Direct Cost: ¥2,100,000)
Fiscal Year 1993: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1992: ¥1,300,000 (Direct Cost: ¥1,300,000)
|
|---|
| Research Abstract |
1).Dose-dependent enzyme suppression in spleen induced by GM1 administration to mice
Our previous studies suggested that the administration of exogenous gangliosides to the body modulates enzymatic networks in the brain. In the present study, we tested whether that is the case with another organ, spleen. By testing the dose response relationship, we found that there is a optimum dose for the effect of enzymatic modulation of GM1 administration. Although the optimum level varied depending on each of the examined hydrolytic enzymes, it usually fell in the range around 50 mug/kg body weight. The findings led us to conclude that the enzyme-modulating actions of gangliosides come not merely from the bizarre actions in vivo of high molecular exogegeous substances.(Chem.Pharm.Bull.'40,1958-1960,1992)
2).Deficiency of galactosidase activity in multiple organs in GM2-deficient mice
WHT/Ht mice are known to have GM2 deficiency especially in the liver. In order to known the relationship of this abnormality to the general metabolism in organs or cells, we compared 17 hydrolytic enzyme activities in the liver, brain, spleen, and kidney between the WHT/Ht mice and control BALB/c mice or without administration of GM2 and GM3. Regardless of the GM2 or GM3 treatment, the galactosidase activity was markedly low in all of the tested organs in the WHT/Ht mice when compared with that in the control animals. This consistency stands in contrast with the known organ-dependency heterogeneity of ganglioside expression and thus indicates independency of the GM2 deficiency from the galactosidase deficiency in this model animal.(J.Clin.Biochem.Nutr., 13,189-197,1992)
|
